| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | ROLLINS INC. REGOFF SCTASK07 | Jun 2, 2026 | |
| Buy | REPLIGEN CORP MARINERS, INC. | Apr 30, 2026 | |
| Sell | REGENERON PHARMACEUTICALS IN | Jan 29, 2026 | |
| Buy | REGENERAL CORP HOLDING CMN | Jan 29, 2026 | |
| Sell | ROCHE DX PHARM | Jan 29, 2026 | |
| Sell | REPLIGEN SERVICES INTEGRATED | Jan 13, 2026 | |
| Buy | REPLIGEN INC. REGEIT 5250/00 | Jan 6, 2026 | |
| Buy | REPLIGEN CORP CMN | Jan 2, 2026 | |
| Sell | Repligen Corporation | Oct 31, 2025 | |
| Sell | Repligen Corporation | Oct 30, 2025 |
This page tracks congressional stock trading activity in Repligen Corporation (RGEN) in the Healthcare sector. Disclosed Capitol has indexed 30 disclosed congressional trades involving RGEN. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of July 2026 — Disclosed Capitol has tracked 30 disclosed congressional trades in Repligen Corporation (RGEN) — 16:8 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jun 2, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 30, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jan 13, 2026 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jan 6, 2026 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jan 2, 2026 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Oct 31, 2025 | Lisa McClain | R | Sale | $1,001 - $15,000 |
| Oct 30, 2025 | Lisa McClain | R | Sale | $1,001 - $15,000 |
Across the 30 disclosed congressional trades in Repligen Corporation (RGEN), members of Congress have reported 8 buys and 16 sells. The average 30-day alpha vs. the S&P 500 is 4.30%.
As of July 2026, corporate insiders at Repligen Corporation have filed 1 SEC Form 4 transaction in RGEN over the past 12 months — including 1 sell worth $80K.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-07-16 | Garland Jason K — CFO | Sale | $80K |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
As of September 2026, Repligen Corporation has 5 federal contract award records on file from USAspending.gov — most recently $169K from the Department of Agriculture on 2026-09-01.
| Award date | Agency | Amount |
|---|---|---|
| 2026-09-01 | Department of Agriculture · Animal and Plant Health Inspection Service | $169K |
| 2026-05-28 | Department of Health and Human Services · Food and Drug Administration | $175K |
| 2026-05-28 | Department of Health and Human Services · Food and Drug Administration | $175K |
| 2021-09-30 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | $14.4M |
| 2016-08-30 | Department of Health and Human Services · Food and Drug Administration | $104K |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Repligen Corporation reported revenue of $738.3M and net income of $48.9M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $204.1M, net income $5.0M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.